Global Hospital Infection Therapeutics Market Report 2021: Market Reached a Value of Approx $11 Billion in 2020 - Trends, Share, Size, Growth, Opportunities and Forecast to 2026 -

·3 min read

DUBLIN, January 24, 2022--(BUSINESS WIRE)--The "Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to's offering.

The global hospital infection therapeutics market reached a value of around US$ 11 Billion in 2020.

Hospital infection therapeutics refers to various pharmaceutical drugs used for the treatment of nosocomial infections. These infections can be acquired at hospitals, nursing homes, rehabilitation facilities and other clinical settings and are usually treated by antiviral, antibacterial and antifungal medicines.

The antibacterial therapeutics consist of cell wall synthesis and protein synthesis inhibitors, such as vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides and tigecycline.

The antifungal therapeutics include caspofungin and Amphotericin B. These drugs aid in preventing the instances of hospital-acquired pneumonia, urinary tract infections (UTIs), gastrointestinal disorders, bloodstream infections and surgical site infections.

The increasing prevalence of hospital-acquired diseases (HAD) is one of the key factors driving the growth of the market

Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Resulting from the deterioration of hygiene facilities in hospitals and other healthcare institutions, there has been a significant increase in the occurrence of hospital-acquired pneumonia and other infections, which is contributing to the increasing demand for hospital infection therapeutics.

Additionally, various product innovations, such as the development of advanced microbial wound care drugs, coverings and vaccines, are acting as other growth-inducing factors. Product manufacturers are developing antimicrobial drugs and pipeline drug molecules that are effective against multi-drug resistant infections and can be used for the treatment of infections with specific symptoms.

Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are expected to drive the market further.

Key Questions Answered in This Report

  • How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?

  • What has been the impact of COVID-19 on the global hospital infection therapeutics market?

  • What are the key regional markets?

  • What is the breakup of the market based on the drug type?

  • What is the breakup of the market based on the indication?

  • What are the various stages in the value chain of the industry?

  • What are the key driving factors and challenges in the industry?

  • What is the structure of the global hospital infection therapeutics market and who are the key players?

  • What is the degree of competition in the industry?

Competitive Landscape

The report has also analysed the competitive landscape of the market with some of the key players being

  • Allergan PLC (AbbVie Inc.)

  • AstraZeneca PLC

  • Bayer Aktiengesellschaft

  • Bristol-Myers Squibb Company

  • F. Hoffmann-La Roche AG (Roche Holding AG)

  • Gilead Sciences Inc.

  • GlaxoSmithKline PLC

  • Johnson & Johnson

  • Merck & Co. Inc

  • Pfizer Inc.

  • Sanofi S.A.

Key Market Segmentation

Breakup by Drug Type

  • Anti-bacterial Drugs

  • Anti-fungal Drugs

  • Anti-viral Drugs

  • Others

Breakup by Indication

  • Blood Stream Infections

  • Urinary Tract Infections

  • Surgical Site Infections

  • Pneumonia

  • Others

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Hospital Infection Therapeutics Market

6 Market Breakup by Drug Type

7 Market Breakup by Indication

8 Market Breakup by Region

9 SWOT Analysis

10 Value Chain Analysis

11 Porters Five Forces Analysis

12 Price Analysis

13 Competitive Landscape

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting